A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cor Medix Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,900 shares of CRMD stock, worth $187,110. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,900
Previous 17,000 11.18%
Holding current value
$187,110
Previous $73,000 108.22%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.64 - $8.23 $322,620 - $729,441
88,632 Added 233.46%
126,596 $1.02 Million
Q2 2024

Aug 14, 2024

SELL
$4.08 - $6.39 $319,500 - $500,394
-78,309 Reduced 67.35%
37,964 $164,000
Q1 2024

May 15, 2024

BUY
$2.94 - $4.24 $222,566 - $320,980
75,703 Added 186.6%
116,273 $492,000
Q4 2023

Feb 14, 2024

SELL
$3.0 - $4.01 $611,211 - $816,985
-203,737 Reduced 83.39%
40,570 $152,000
Q3 2023

Nov 14, 2023

BUY
$3.6 - $4.46 $532,249 - $659,397
147,847 Added 153.27%
244,307 $903,000
Q2 2023

Aug 14, 2023

SELL
$3.94 - $5.8 $287,856 - $423,748
-73,060 Reduced 43.1%
96,460 $381,000
Q1 2023

May 15, 2023

SELL
$3.22 - $4.61 $76,793 - $109,943
-23,849 Reduced 12.33%
169,520 $701,000
Q4 2022

Feb 14, 2023

BUY
$2.81 - $4.45 $375,306 - $594,346
133,561 Added 223.32%
193,369 $816,000
Q3 2022

Nov 14, 2022

SELL
$2.82 - $7.52 $153,828 - $410,208
-54,549 Reduced 47.7%
59,808 $169,000
Q2 2022

Aug 15, 2022

BUY
$2.73 - $5.61 $233,641 - $480,120
85,583 Added 297.43%
114,357 $460,000
Q1 2022

May 16, 2022

BUY
$3.83 - $6.24 $69,947 - $113,961
18,263 Added 173.75%
28,774 $158,000
Q4 2021

Feb 14, 2022

SELL
$4.47 - $5.56 $46,139 - $57,390
-10,322 Reduced 49.55%
10,511 $47,000
Q3 2021

Nov 15, 2021

SELL
$4.46 - $7.11 $41,420 - $66,030
-9,287 Reduced 30.83%
20,833 $97,000
Q2 2021

Aug 16, 2021

BUY
$6.05 - $10.09 $6,757 - $11,270
1,117 Added 3.85%
30,120 $206,000
Q1 2021

May 17, 2021

SELL
$6.84 - $17.58 $377,930 - $971,347
-55,253 Reduced 65.58%
29,003 $290,000
Q4 2020

Feb 16, 2021

BUY
$5.0 - $9.15 $337,660 - $617,917
67,532 Added 403.8%
84,256 $626,000
Q3 2020

Nov 16, 2020

SELL
$3.96 - $6.15 $6,593 - $10,239
-1,665 Reduced 9.05%
16,724 $101,000
Q2 2020

Aug 14, 2020

SELL
$3.08 - $6.56 $32,025 - $68,210
-10,398 Reduced 36.12%
18,389 $116,000
Q1 2020

May 15, 2020

BUY
$2.35 - $7.08 $38,135 - $114,894
16,228 Added 129.21%
28,787 $103,000
Q4 2019

Feb 14, 2020

SELL
$4.96 - $7.75 $26,040 - $40,687
-5,250 Reduced 29.48%
12,559 $91,000
Q3 2019

Nov 14, 2019

BUY
$6.38 - $9.69 $113,621 - $172,569
17,809 New
17,809 $113,000

Others Institutions Holding CRMD

About CorMedix Inc.


  • Ticker CRMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,208,200
  • Market Cap $408M
  • Description
  • CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...
More about CRMD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.